MEDIUS HOLDINGS Co.,Ltd.
3154・Prime Market・Wholesale Trade
Medical Equipment Sales Business
The core business, accounting for approximately 98% of group sales. Engages in medical equipment sales and maintenance for domestic hospitals.
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (cumulative Q3, FY2026 (ending June 2026)) | ¥222,909 million | ¥214,929 million (cumulative Q3, FY2025 (ended June 2025)) | ↑ |
| Gross profit (cumulative Q3, FY2026 (ending June 2026)) | ¥25,220 million | Up 3.4% year on year (cumulative Q3) | ↑ |
| Segment profit (operating profit) (cumulative Q3, FY2026 (ending June 2026)) | ¥7,506 million | ¥8,260 million (cumulative Q3, FY2025 (ended June 2025)) | ↓ |
| Net sales (full year, FY2025 (ended June 2025)) | ¥282,688 million | — | — |
| Segment profit (full year, FY2025 (ended June 2025)) | ¥10,447 million | — | — |
| Gross profit (full year, FY2025 (ended June 2025)) | ¥32,117 million | — | — |
Business Details
The company sells medical equipment (fixtures and consumables) procured from domestic medical device manufacturers, distributors, and trading companies to domestic hospitals and other medical facilities, and also provides repair, after-sales service, and maintenance under maintenance contracts for previously sold medical equipment. With growth in surgical/examination cases and new customer acquisition centered on the orthopedic and cardiovascular fields as its growth engine, the segment also supports the management improvement of medical institutions through value-added proposals combining SPD (Supply Processing & Distribution) and various solution tools.
Recent Overview
Net sales rose 3.7% year on year, but profit declined 9.1% due to increased costs, resulting in higher revenue but lower profit.
In the cumulative nine months of FY2026 (ending June 2026), net sales increased to ¥222,909 million (up 3.7% year on year) and gross profit increased to ¥25,220 million (up 3.4% year on year), driven by growth in surgical/examination cases and new customer acquisition centered on the cardiovascular and orthopedic fields, resulting in higher revenue and profit. On the other hand, selling, general and administrative expenses increased due to higher personnel costs from staff hiring and base pay increases associated with business expansion, as well as rising logistics costs from higher delivery unit prices and increased volume, resulting in segment profit (operating profit) of ¥7,506 million (down 9.1% year on year), a decline in profit. Regarding changes in the scope of consolidation, Reps Co., Ltd. was newly consolidated (effective July 1, 2025), while Noah International Co., Ltd. was excluded following an absorption-type merger (effective October 1, 2025).
Key Products
Growth Drivers
- Increase in the number of surgical and examination cases, centered on the orthopedic and cardiovascular fields
- Continued progress in acquiring new customers
- Expansion of the business base through M&A (including internal group reorganization and establishment of new subsidiaries)
- Expansion of solution businesses such as SPD, SURGЕЛANE®, and meccul®
- Gradual market expansion in demand for medical equipment amid an aging population
Risks
- Downward pressure on drug and material prices due to medical fee schedule revisions
- Decline in profit margins due to rising personnel costs and elevated logistics costs
- Rising procurement costs due to yen depreciation, persistently high energy prices, and the situation in Iran, among other factors
- Intensifying competition and a downward trend in selling prices amid medical cost containment policies
- Trend of consolidation of business partners by medical device manufacturers toward major dealers
Last updated: September 25, 2025